EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy

Goreti Ribeiro Morais iD, Gabriel C Nwokolo iD, Harriet N L Lamptey Mills iD, Richard T Wheelhouse iD, Robert A Falconer iD

Molecules · 27.03.2026 · 31 (7) · 1103

DOI: 10.3390/molecules31071103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 27.03.2026. Verfasst von Goreti Ribeiro Morais und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK. Hauptthemen laut MEDLINE: Triazenes, Temozolomide, Prodrugs, Dacarbazine. Die Arbeit nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Masonic Charitable Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide and dacarbazine are untargeted anticancer prodrugs that have been widely employed in the treatment of melanoma and glioblastoma. These agents decompose into a short-lived monomethyl triazene intermediate, culminating in the release of a methyl diazonium cation that serves as the DNA-alkylating species responsible for tumour destruction. However, due to their high chemical lability, these agents have been associated with chemotherapy resistance, mutagenicity, tumour relapse, and significant off-target toxicity. One promising strategy towards the resolution of these limitations involves the design of arylmethyl triazene prodrugs, which enable targeted tumour-specific drug delivery. This review explores the various approaches used to selectively deliver alkyl aryl triazenes as alternatives to current therapies. It highlights early chemical strategies such as N-acylation and etherification of monomethyl triazenes, along with associated kinetic studies. The selective activation of novel triazenes in murine and human melanoma cells through a tyrosinase-responsive promoiety is discussed. Recent progress in nitroaromatic-based prodrugs designed to exploit the hypoxic microenvironment of glioblastoma is also examined. Additionally, we summarise the development of combi-triazenes and their underlying chemistries, which enable the simultaneous release of two active therapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriazenesTemozolomideProdrugsDacarbazineAntineoplastic AgentsNeoplasmsHumansAnimals

Stichwörter der Autor:innen

anticancer activityaryl triazenesdecompositionhybridsmetabolismprodrugssynthetic strategiestargeting

Substanzen

TriazenesTemozolomideProdrugsDacarbazineAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK.

ORCID-Profile: Goreti Ribeiro Morais, Gabriel C Nwokolo, Harriet N L Lamptey Mills, Richard T Wheelhouse, Robert A Falconer

Förderung

  • Masonic Charitable Foundation

Zitieren

APA

Ribeiro Morais, G., Nwokolo, G. C., Lamptey Mills, H. N. L., Wheelhouse, R. T., & Falconer, R. A. (2026). Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy. Molecules, 31(7), 1103. https://doi.org/10.3390/molecules31071103

Vancouver

Ribeiro Morais G, Nwokolo GC, Lamptey Mills HNL, Wheelhouse RT, Falconer RA. Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy. Molecules. 2026;31(7):1103. doi:10.3390/molecules31071103

BibTeX
@article{RibeiroMorais2026,
  author = {Ribeiro Morais, Goreti and Nwokolo, Gabriel C and Lamptey Mills, Harriet N L and Wheelhouse, Richard T and Falconer, Robert A},
  title = {Exploiting Methyl Triazenes as Attractive Alternatives to Temozolomide and Dacarbazine for Cancer Therapy},
  journal = {Molecules},
  year = {2026},
  volume = {31},
  number = {7},
  pages = {1103},
  doi = {10.3390/molecules31071103}
}
Kostenlos starten →